Medtronic has completed its acquisition of SPR Therapeutics, a pain management medtech company, for $650 million.
SPR Therapeutics develops percutaneous peripheral nerve stimulation therapies for chronic and acute pain management. Nearly 50 million adults in the U.S. are affected by chronic pain, according to a July 16 news release from Medtronic.
SPR’s Sprint PNS System is cleared by the FDA and provides pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant.
Medtronic expects the acquisition to be minimally dilutive to Medtronic adjusted earnings per share in fiscal year 2027 and neutral to accretive thereafter, the release said.
